{"id":96038,"date":"2017-01-25T13:28:32","date_gmt":"2017-01-25T13:28:32","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=96038"},"modified":"2017-01-25T13:28:32","modified_gmt":"2017-01-25T13:28:32","slug":"creative-biolabs-released-siat-immunogenicity-system-to-support-drug-candidate-research","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/creative-biolabs-released-siat-immunogenicity-system-to-support-drug-candidate-research_96038.html","title":{"rendered":"Creative Biolabs Released SIAT\u00ae Immunogenicity System to Support Drug Candidate Research"},"content":{"rendered":"
\"\"<\/a><\/div>\n
Based on the academic group and expertise, Creative Biolabs has established the Sensitive Immunogenicity Assessment Technology\u00ae (SIAT\u00ae) system to support drug candidate research.<\/div>\n

Creative Biolabs offers comprehensive list of immunogenicity assessment services<\/a> for biotherapeutic drug candidates. With the common efforts of its scientists, Creative Biolabs has developed the Sensitive Immunogenicity Assessment Technology®<\/sup> (SIAT®<\/sup>) system. This system can be applied to evaluate the immunogenicity potential for a wide range of biotherapeutic drug candidates.<\/p>\n

Its comprehensive SIAT®<\/sup> system provides in silico<\/em>, in vitro<\/em>, ex vivo<\/em>, in vivo<\/em> immunogenicity assessment and ADA assay services. In addition, it also provides de-immunization service if high immunogenicity potential is identified. All these services will assist customers in candidate selection and optimization in different phases of new biotherapeutic drug development.<\/p>\n

Featured Services of Creative Biolabs’ SIAT®<\/sup> System includes in silico<\/em> immunogenicity assessment, in vitro<\/em> class II HLA binding assay, ex vivo<\/em> immunogenicity assessment, in vivo<\/em> immunogenicity assessment, anti-drug antibody (ADA) assay and de-immunization service.<\/p>\n

Biotherapeutic drugs, including protein, enzyme, antibody, conjugate antibodies<\/a>, are of significant value in the treatment of various diseases. Compared to small molecule drugs, the advantages of biotherapeutic drugs are mainly manifested by prolonged half-life, high target specificity, and low intrinsic toxicity.<\/p>\n

The immune responses to biotherapeutic drugs decrease the efficacy of the drugs due to faster clearance of the drugs as antigens. In addition, unwanted immune system activation raises concerns of patient safety for issues, such as rapid and enormous cytokine release. Therefore, immunogenicity risk management of biotherapeutic drugs and biosimilar biologics is critical for successful development. <\/p>\n

About Creative Biolabs<\/strong><\/p>\n

Creative Biolabs is specialized in providing custom biotechnology and pharmaceutical services that cover the full scope of biotechnology needs of early drug discovery and drug development, such as polyglutamylation<\/a>. As a trusted provider of the most cost-effective outsourcing solutions, Creative Biolabs has been working for a large number of clients from biotechnology and pharmaceutical companies as well as government and academic research laboratories all over the world.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Creative Biolabs
Contact Person:<\/strong> Candy Swift
Email:<\/strong> marketing@creative-biolabs.com
Phone:<\/strong> 1-631-619-7922
Address:<\/strong>45-1 Ramsey Road
City:<\/strong> Shirley
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> http:\/\/www.creative-biolabs.com<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Based on the academic group and expertise, Creative Biolabs has established the Sensitive Immunogenicity Assessment Technology\u00ae (SIAT\u00ae) system to support drug candidate research. Creative Biolabs offers comprehensive list of immunogenicity assessment services for biotherapeutic drug candidates. With the common efforts … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-96038","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/96038","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=96038"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/96038\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=96038"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=96038"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=96038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}